Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sandra V. Dixon"'
Autor:
Vincent Siu, Timothy Mant, Mira Patel, Noel Landsman, Joshua Lehrer-Graiwer, Moji Awogbade, Kobina Dufu, John B. Porter, Daniel D. Gretler, Athiwat Hutchaleelaha, Sandra V. Dixon, Claire Hemmaway, Paul Telfer, D. Mark Layton, Jo Howard, Margaret Tonda
Publikováno v:
Blood. 133:1865-1875
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxeloto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7890326c7b563b083e7615d4cfa0cca0
https://doi.org/10.1182/blood-2018-08-868893
https://doi.org/10.1182/blood-2018-08-868893
Autor:
Sean H. Lim, Kerry L. Cox, Ruth R. French, Kathleen N. Potter, H.T. Claude Chan, Stephen A. Beers, Martin J. Glennie, Emily L Williams, Peter Johnson, Andrew Davies, Andrew T M Vaughan, C. Ian Mockridge, Sandra V. Dixon, Mark S. Cragg, Margaret Ashton-Key, David Oscier
Publikováno v:
Blood. 118:2530-2540
The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that resistance could be explained, in part, by internalization of rituximab (type I anti-CD20) from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50254f7557436e287f85767eb91af5d7
https://doi.org/10.1182/blood-2011-01-330357
https://doi.org/10.1182/blood-2011-01-330357
Autor:
Peter S. Friedmann, Eugene Healy, Michael R. Ardern-Jones, Chris Pickard, Sandra V. Dixon, Michelle E. Oakford, Peter M. Lackie, Suzannah August
Publikováno v:
Journal of Investigative Dermatology. 131:1950-1953
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::664fb48b0c253941f05871cb04966ccb
https://doi.org/10.1038/jid.2011.146
https://doi.org/10.1038/jid.2011.146
Autor:
Connie M. Piccone, Clark Brown, Victor R. Gordeuk, Erica Fong, Miguel R. Abboud, Winfred C. Wang, Lewis L. Hsu, Adlette Inati, Margaret Tonda, Carolyn Hoppe, Gerald M. Woods, Robert I. Liem, Sandra V. Dixon, Richard A. Drachtman, Joshua Lehrer-Graiwer, Carla Washington
Publikováno v:
Blood. 132:509-509
Background: Sickle cell disease (SCD) is a genetic disorder caused by a mutated hemoglobin S (HbS) that polymerizes in the deoxygenated state and triggers the downstream effects of red blood cell deformation (sickling), hemolysis, vaso-occlusion, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ee4e729a858fdbf36142c3122bac42
https://doi.org/10.1182/blood-2018-99-117510
https://doi.org/10.1182/blood-2018-99-117510
Autor:
Stephen A. Beers, Peter Johnson, Hyungjin Kim, David A. Johnston, Kerry L. Cox, J. Sjef Verbeek, Sahan S. Wijayaweera, Sean H. Lim, Martin J. Glennie, Ruth R. French, H.T. Claude Chan, Regina Mora Vidal, Timothy C. Jarrett, Sandra V. Dixon, Jonathan P. Kerr, Mark S. Cragg
Publikováno v:
Blood, 115(25), 5191-5201
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43ea084d379421e68410774488f2f80d
https://doi.org/10.1182/blood-2010-01-263533
https://doi.org/10.1182/blood-2010-01-263533
Autor:
Carolyn Hoppe, Michelle Green, Ganesh Balaratnam, Josh Lehrer, Margaret Tonda, Sandra V. Dixon, Erica Fong, Carla Washington, Clark Brown, Winfred C. Wang, Adlette Inati, Athiwat Hutchaleelaha
Publikováno v:
Blood. 130:980-980
Background: Sickle cell disease (SCD) is caused by polymerization of hemoglobin S (HbS), resulting in hemolysis and vaso-occlusion. Currently, no therapy achieving direct pancellular inhibition of HbS polymerization is available for adults or childre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46794ff9822fdc49ae6607e33d919b6c
https://doi.org/10.1182/blood.v130.suppl_1.980.980
https://doi.org/10.1182/blood.v130.suppl_1.980.980
Autor:
Stephen A. Beers, Mark S. Cragg, Daniel Ajona, Ruth R. French, C. Ian Mockridge, J. Sjef Verbeek, Sandra V. Dixon, Ali Roghanian, Ann L. White, Martin J. Glennie, Aymen Al-Shamkhani, Alison L. Tutt, H.T. Claude Chan
Publikováno v:
Journal of Immunology, 187(4), 1754-1763
A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal FcγR binding profiles of other anti-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964b9c4959ecabc7b142a3d2994a67a1
https://pubmed.ncbi.nlm.nih.gov/21742972
https://pubmed.ncbi.nlm.nih.gov/21742972
Autor:
Sandra V. Dixon, Kevin A. Wilkinson, Mahmood Khan, Ann L. White, Sonya James, Aymen Al-Shamkhani, Alison L. Tutt, Adam F. Cunningham, Fernanda Castro, Martin J. Glennie, Jessica Hitchcock
Publikováno v:
Immunology.
Summary In this study, we investigated the mouse dendritic cell (DC) receptor, complement receptor 4 (CR4; CD11c/CD18), as an immunotarget for triggering humoral immunity. Comparison of antibody titres generated against a panel of 13 anti-antigen-pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9080b2cc5c0387e745269ddcbe79c33
https://doi.org/10.1111/j.1365-2567.2010.03285.x
https://doi.org/10.1111/j.1365-2567.2010.03285.x